Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as ...

In 2024, Adimab and its partners initiated discovery on 62 new therapeutic programs, bringing the total number of ...